News & Events about Penumbra Inc.
Penumbra (NYSE:PEN Get Rating) had its price target raised by Truist Financial from $228.00 to $255.00 in a report published on Tuesday , Benzinga reports. Truist Financial currently has a buy rating on the stock. Other research analysts have also recently issued research reports about the company. ...
Globe Newswire
3 months ago
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, ...
Analysts have provided the following ratings for Penumbra (NYSE:PEN) within the last quarter:
Latest Ratings for PEN
DateFirmActionFromTo Mar 2022NeedhamInitiates Coverage OnHold Feb 2022CitigroupMaintainsBuy Feb 2022JP MorganMaintainsOverweight
View More Analyst Ratings for PEN
View the ...
Business Wire
4 months ago
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, and Asahi Intecc Co., a leading Japanese medical device manufacturer, announced that they will collaborate to introduce Penumbras Indigo Aspiration System into the Japanese market upon regulatory approval. This...
Business Wire
4 months ago
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced that its RED Reperfusion Catheters have secured CE Mark (Conformit Europenne) and are now commercially available in Europe. The catheters are part of the companys Penumbra System, which is a fully...